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peptide (SLP) to a MART-1aa26-35 recognizing CD8
+ T 
cell line, IL-4 MoDC proved more potent cross-prim-
ers of antigen-specific CD8+ T cells when loaded with 
blebs. The latter is likely due to the observed greater 
capacity of IL-4 MoDC to ingest apoptotic blebs. In 
conclusion, our data indicate the use of IFNα MoDC 
over IL-4 MoDC in the context of DC vaccination with 
SLP, whereas IL-4 MoDC are preferred for vaccination 
with bleb-derived antigens.
Keywords Monocyte-derived dendritic cell · IL-4 · 
IFNα · Antigen presentation · Vaccination
Abbreviations
ACR  Apoptotic cell remnants
AML  Acute myeloid leukemia
CFSE  Carboxyfluorescein succinimidyl ester
CR  Complement receptor
DC  Dendritic cells
HLA  Human leukocyte antigen
IFN  Interferon
IL  Interleukin
imMoDC  Immature MoDC
MART-1  Melanoma-associated antigen recognized by 
T cells 1
matMoDC  Mature MoDC
MLR  Mixed leukocyte reaction
MoDC  Monocyte-derived dendritic cells
PBL  Peripheral blood lymphocytes
PBMC  Peripheral blood mononuclear cells
PGE-2  Prostaglandin E-2
SLP  Synthetic long peptide
TAA  Tumor-associated antigens
TH  T helper
TNFα  Tumor necrosis factors
Abstract Dendritic cells (DC) vaccination is a potent 
therapeutic approach for inducing tumor-directed 
immunity, but challenges remain. One of the particu-
lar interest is the induction of an immune response tar-
geting multiple (unknown) tumor-associated antigens 
(TAA), which requires a polyvalent source of TAA. 
Previously, we described the preferred use of apop-
totic cell-derived blebs over the larger apoptotic cell 
remnants, as a source of TAA for both in situ load-
ing of skin-resident DC and in vitro loading of mono-
cyte-derived DC (MoDC). Recent reports suggest that 
MoDC cultured in the presence of GM-CSF supple-
mented with IFNα (IFNα MoDC), as compared to IL-4 
(IL-4 MoDC), have an increased capacity to cross-
present antigen to CD8+ T cells. As culture conditions, 
maturation methods and antigen sources differ between 
the conducted studies, we analyzed the functional dif-
ferences between IL-4 MoDC and IFNα MoDC, loaded 
with blebs, in a head-to-head comparison using com-
monly used protocols. Our data show that both MoDC 
types are potent (cross-) primers of CD8+ T cells. 
Whereas IFNα MoDC were more potent in their capac-
ity to cross-present a 25-mer MART-1 synthetic long 
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Introduction
Targeting residual leukemic cells using dendritic cell (DC) 
vaccination is a promising therapeutic strategy for the treat-
ment of acute myeloid leukemia (AML), as well as other 
types of cancer. Since the use of DC was first proposed for 
active anti-tumor vaccination by Banchereau and Stein-
man [1], strategies for loading tumor-associated antigen 
(TAA) onto DC have been exploited intensively (reviewed 
for AML in [2, 3]). Loading DC with TAA is an essential 
step in inducing tumor-directed T cell responses, and the 
use of different antigenic sources has proven to affect DC 
function [2, 4–6], as well as the number of tumor antigen 
epitopes. Different strategies to load DC with TAA for 
anti-tumor T cell priming depend on different (intra)cel-
lular routes of antigen processing. One of the most impor-
tant capacities of DC in the context of antigen loading is 
their ability to ingest and cross-present exogenous antigen, 
a mechanism exploited to load DC with a variety of TAA 
sources for vaccination purposes. Exogenous antigens [e.g., 
from apoptotic cells or synthetic long peptides (SLP)] are 
most efficiently presented in complex with HLA class II 
[7]. However, DC can present exogenous TAA in HLA 
class I molecules by means of cross-presentation [8]. The 
exact mechanism by which cross-presentation occurs and 
which DC types are most potent in their ability to cross-
present antigen in vivo remains unclear (reviewed in [9]). 
However, most DC subsets are capable of performing this 
task and appear to achieve this with similar efficacy [10]. 
Previously, we have reported that apoptotic blebs, derived 
from apoptotic AML cells, are a superior source of TAA for 
the in situ loading of human skin-resident DC, which take 
up and cross-present TAA from blebs to a higher degree 
as compared to ACR [11]. Moreover, IL-4 MoDC loaded 
with isolated apoptotic blebs increased CD4+ T cell pro-
liferation and T helper (TH) type I skewing (based on IFNγ 
production), as compared to using ACR; importantly, we 
have also shown that bleb-loaded IL-4 MoDC induce TAA-
specific CD8+ T cells with higher avidity [6].
Monocytes are commonly differentiated into MoDC 
in the presence of GM-CSF and IL-4. Currently, there is 
growing interest in the use of MoDC differentiated in the 
presence of GM-CSF and interferon-α (IFNα), since IFNα 
MoDC have been described to be more potent in cross-pre-
senting antigen [12–14], which would be beneficial for DC-
based tumor vaccines. However, the culture and maturation 
methods, as well as the antigen sources used in these stud-
ies vary. For instance, the culture periods used for the gen-
eration of both types of MoDC generally differ, i.e., a 3-day 
culture period for IFNα MoDC and a 5-day culture period 
for IL-4 MoDC. In order to synchronize the cultures from 
the same donors, most studies either increased the IFNα 
MoDC culture time or shortened IL-4 MoDC differentia-
tion accordingly. Moreover, varying modalities have been 
used to induce DC maturation in these comparative studies, 
e.g., TNFα, lipopolysaccharides or CD40 ligation [12, 13], 
as well as different sources of antigen, e.g, soluble protein 
and apoptotic cells [12–14].
To determine the preferred DC type to serve as a vehicle 
for AML-derived apoptotic bleb vaccines, we conducted a 
head-to-head comparison of IL-4 MoDC and IFNα MoDC. 
These MoDC types were cultured using the commonly 
used culture protocols (5- vs. 3-day, respectively), matured 
with a maturation cocktail consisting of IL-1β, IL-6, TNFα, 
PGE-2, and subsequently analyzed for their immunophe-
notype, endocytic capacity for apoptotic blebs and soluble 
antigen, and their ability to prime naive T cells, to cross-
present, and to cross-prime antigen-specific T cells.
Materials and methods
Generation of apoptotic cell fractions
In order to facilitate assessment of antigen-specific CD8+ 
T cell activation and induction, HL60 AML cells were ret-
rovirally transduced with melanoma-associated antigen 
recognized by T cells (MART-1), as described previously 
[15]. Apoptotic cell fractions were generated as described 
previously [6]. In short, apoptosis was induced by leaving 
the HL60 cells for 2 h at 42 °C in serum-free RPMI (Gibco, 
Paisley, UK), followed by γ-irradiation at 5000 rad. After 
48–72 h, ACR were removed from the preparation by cen-
trifuging at 600×g, after which the resulting supernatant 
was spun down at 4000×g to isolate the apoptotic blebs. 
Next, the blebs were washed with PBS, and the protein 
concentration was determined using a ND-1000 Nanodrop 
spectrophotometer (Thermo Fisher Scientific, Breda, the 
Netherlands). The isolated blebs were stored in liquid nitro-
gen until use.
Dendritic cell culture
Monocytes were isolated from peripheral blood mononuclear 
cells (PBMC) of healthy donors, after informed consent, by 
magnetically activated cell sorting using CD14 Microbeads 
(Miltenyi Biotec, Utrecht, the Netherlands). Isolated mono-
cytes were cultured in the presence of 800 U/ml GM-CSF 
(Peprotech, the Netherlands), supplemented with either 500 
U/ml IL-4 (Peprotech, the Netherlands) for the generation of 
IL-4 MoDC, or 1000 U/ml IFNα A/D (R&D Systems) for 
the induction of IFNα MoDC. IL-4 MoDC were cultured 
for 5 days and IFNα MoDC for 3 days, as most frequently 
described in literature [12–14, 16].
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Dendritic cell immunophenotype, cytokine production, 
and loading
After differentiation, MoDC were isolated and the 
immunophenotype was determined by flow cytometry, 
using FITC-labeled, PE-labeled, APC, Horizon V450, 
or PeCy7-labeled antibodies against HLA-ABC, HLA-
DR, CD1a, CD14, CD36, CD40, CD80, CD83, CD86, 
CLEC9a, Lox-1, CD18/CD11b (complement recep-
tor 3), and CD18/CD11c (complement receptor 4) (all 
obtained from BD Biosciences), and the expression 
levels were subsequently analysed using flow cytom-
etry (LSRFortessa™, BD Biosciences); the data were 
analyzed using FACS Diva software (BD Biosciences). 
MoDC cytokine production was analyzed, after overnight 
co-culture with irradiated CD40 ligand-expressing J558 
cells and 1000 U/ml IFNγ (Sanquin, Amsterdam, the 
Netherlands), using an inflammatory cytokine bead array 
(BD Biosciences, Breda, the Netherlands). For MoDC 
loading, 2 × 105 MoDC were loaded with 40 µg of blebs 
in the presence of the differentiation cytokine cocktails 
(GM-CSF/IL-4, or GM-CSF/IFNα), and 1 h after initi-
ating loading, maturation was induced by IL-1β (10 ng/
ml), TNFα (200 U/ml, both from Sanquin, Amsterdam, 
the Netherlands), IL-6 (10 ng/ml, R&D systems, Abing-
don, UK), and PGE2 (10 ng/ml, Sigma-Aldrich, Zwijn-
drecht, the Netherlands).
In order to determine uptake, 40 μg blebs were labeled 
with 0.5 μM carboxyfluorescein succinimidyl ester (CFSE) 
(Invitrogen, Breda, the Netherlands), and cultured over-
night with 2 × 05 PKH26 red-labeled (1 μM, Sigma-
Aldrich) MoDC. The percentage of double-positive cells 
was analyzed using flow cytometry (LSRFortessa™), as a 
measure of uptake.
Endocytosis of soluble proteins was analyzed by add-
ing either dextran-FITC (2 μg/ml, Sigma-Aldrich) or Luci-
fer Yellow (2 μg/ml, Sigma-Aldrich) to immature IL-4 or 
IFNα MoDC for 1 h, after which the uptake was analyzed 
using flow cytometry (LSRFortessa™).
Mixed leukocyte reaction
Peripheral blood lymphocytes (PBL) were isolated after 
informed consent from PBMC of healthy donors, by 
depleting CD14+ cells using CD14 Microbeads (Miltenyi 
Biotec). PBL were stored in liquid nitrogen until further 
use. PBL were labeled with 1 µM CFSE (Invitrogen) and 
plated in a 96-well plate at 1 × 105 per well. Mature bleb-
loaded MoDC were added to the wells at DC/PBL ratios 
of 1:5, 1:10, or 1:20, and CD3+CD4+ and CD3+CD8+ T 
cell proliferations were analyzed using flow cytometry 
after 6 days. The day 6 supernatant was analyzed for T cell 
cytokines, using a TH1/TH2/TH17 cytokine bead array 
(BD Biosciences, Breda, the Netherlands).
Antigen cross‑presentation
HLA-A2+ MoDC were loaded with different concentra-
tions of a 25-mer MART-1aa16-40L SLP for 2 h, after which 
MoDC maturation was induced by adding IL-1β, IL-6, 
TNFα, and PGE-2. Blebs were loaded as described above, 
at 40 µg per 2 × 105 MoDC. After loading SLP or blebs 
overnight, MoDC were harvested and co-cultured for 
5 h with a MART-1aa25-36 recognizing CD8
+ T cell line 
(MART-1 T cell line, >95 % pure), in the presence of 1 μl/
ml GolgiStop™ (BD Biosciences). Next, the cells were 
washed and stained with an APC-labeled MART-1aa26-35 
HLA-A2 dextramer (Immudex, Denmark) for 15 min, fol-
lowed by 15 min of staining with Horizon V450 or FITC-
labeled CD3 and CD8 mAbs (both BD Biosciences). After 
washing, the cells were fixed and permeabilized using BD 
Cytofix/Cytoperm™ solution (BD Biosciences), following 
manufacturer’s protocol. Finally, intracellular IFNγ (BD 
Biosciences) was stained for 30 min at 4 °C, after which 
the cells were washed and IFNγ production was analyzed 
using flow cytometry (LSRFortessa™, BD Biosciences), as 
a measure of activation.
CD8+ T cell priming
CD14+ from HLA-A2+ PBMC were differentiated into 
either IL-4 MoDC (5 days) or IFNα MoDC (3 days), 
and CD8+ and CD14CD8− cells were stored in liquid 
nitrogen for further use. IFNα MoDC or IL-4 MoDC 
were loaded with blebs or MART-1aa26-35L peptide, and 
plated at 1 × 105 per well. Autologous CD8+ T cells and 
irradiated CD14−CD8−cells were added to the loaded 
MoDC at 1 × 106 per well, supplemented with 20 U/
ml IL-7, 10 ng/ml IL-12 (both Sanquin), and 10 ng/ml 
IL-6 (R&D systems) in a final volume of 2 ml in Yssel’s 
medium [17]. After 24 h, 10 ng/ml IL-10 (eBioscience, 
Vienna, Austria) was added to the co-cultures. The prim-
ing cultures were restimulated after 9 or 11 days, and 
subsequently every 7 days, with freshly loaded (thawed) 
IFNα MoDC or IL-4 MoDC, respectively. The percent-
age of dextramer-positive cells was analyzed before each 
restimulation.
T cell avidity assay
JY cells were loaded for 3 h with MART-1aa26-35L peptide 
in serum-free RPMI, at concentrations ranging from 10 μM 
to 1 pM, in the presence of 3 μg/ml β2-microglobulin. 
5 × 105 CD3+CD8+T cells were cultured with 5 × 105 
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peptide loaded JY, in the presence of 1 μl/ml GolgiStop™ 
(BD Biosciences) for 5 h, after which intracellular IFNγ 
production was assessed as described above.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 
version 5 for Windows (GraphPad Software Inc.), using a 
paired two-tailed Student’s t test, Fisher’s exact test, or a 
Wilcoxon matched-pairs signed-rank test as indicated. Dif-
ferences with p values ≤0.05 were regarded significant.
Results
Differences in MoDC phenotype post‑differentiation 
and maturation
We first assessed MoDC phenotype after a 3- or 5-day 
differentiation period for IFNα or IL-4 MoDC, respec-
tively (Fig. 1a). IFNα MoDC had significantly higher 
expression levels of HLA class II (p = 0.04), and CD14 
(p = 0.0005), as compared to IL-4 MoDC. Moreover, IFNα 
MoDC showed a higher expression of CD80 (p = 0.01) 
and CD86 (p = 0.03). Next, we assessed the MoDC phe-
notype upon maturation induction in the presence of apop-
totic blebs. In contrast to the immature state, IL-4 MoDC 
displayed a significantly higher expression of both HLA 
class I (p = 0.0006) and HLA class II (p = 0.01) and CD1a 
(p = 0.009) following loading with blebs and subsequent 
maturation (Fig. 1b). Moreover, IL-4 MoDC had a sig-
nificantly higher expression of CD40 (p = 0.003), CD80 
(p = 0.002), CD83 (p = 0.001), and CD86 (p = 0.002), 
whereas IFNα MoDC retained a higher CD14 expression 
after maturation (p = 0.009). After inducing maturation, 
IFNα MoDC down-regulated CD1a, compared to their 
immature expression levels (p = 0.02), at levels lower than 
those on mature IL-4 MoDC (p = 0.002).
IL‑4 MoDC are more potent in their ability to ingest 
blebs and soluble antigen
As the ingestion of exogenous antigen by MoDC is essen-
tial for the (cross-) priming of antigen-specific T cells, we 
analyzed the capacity of IFNα and IL-4 MoDC to phago-
cytose apoptotic blebs. After overnight co-culture, a sig-
nificantly higher percentage of IL-4 MoDC had ingested 
blebs as compared to IFNα MoDC, in an immature (85 vs. 
Fig. 1  Analysis of MoDC immunophenotype and endocytic capac-
ity. a Immunophenotype of monocyte-derived dendritic cells (MoDC) 
generated in the presence of either GM-CSF and IL-4 (black bars), 
or GM-CSF and IFNα (white bars), for, respectively, 5 or 3 days, 
(n = 4). *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001. b Immunophenotype 
of MoDC 48 h after loading with blebs and subsequent maturation 
induction by IL-1β, IL-6, TNFα, and PGE-2 (n = 4). *p < 0.05, 
**p ≤ 0.01, ***p ≤ 0.001. c Fluorescently labeled MoDC were co-
cultured overnight with fluorescently labeled blebs, after which the 
percentage of double-positive IL-4 (black bars), or IFNα MoDC 
(white bars), were quantified (apoptotic blebs). Alternatively, MoDC 
were cultured in the presence of Lucifer Yellow (pinocytosis), or 
dextran-FITC (receptor-mediated endocytosis). (n = 4). d Expression 
levels of scavenger receptors on immature IL-4 (black bars), or IFNα 
MoDC (white bars), using flow cytometry (n = 4). Statistical signifi-
cance was for all figures determined using a Student’s t test
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53 %, p = 0.0007; Fig. 1c, apoptotic blebs) as well as a 
mature state (75 vs., 55 %, p = 0.025, data not shown). In 
order to determine whether this difference in the capacity 
to ingest blebs could be explained by different expression 
levels of receptors involved in antigen uptake and cross-
presentation, we analyzed the expression levels of CD36, 
Clec9a, Lox-1, complement receptors (CR)3, and CR4 on 
IFNα versus IL-4 MoDC (Fig. 1d). We observed similar 
levels of expression of the tested receptors on both imma-
ture (Fig. 1d) and mature IFNα and IL-4 MoDC (data 
not shown). Lectin receptors are described to play a role 
in apoptotic cell uptake [18], and to assess whether IL-4 
MoDC had an increased pinocytosis and lectin receptor-
mediated antigen uptake, we performed a 1 h co-culture 
with either Lucifer Yellow (Fig. 1c, pinocytosis) or dextran-
FITC (Fig. 1c, receptor-mediated endocytosis), respec-
tively. Next, to an increased uptake of blebs, we observed 
an increased uptake of both Lucifer Yellow (p = 0.02) and 
a near-significant increase in the uptake of dextran-FITC 
(p = 0.06) by IL-4 MoDC, as compared to IFNα MoDC.
Cytokine release and allogeneic T cell induction
IFNα or IL-4 MoDC were cultured overnight in the pres-
ence of IFNγ and the CD40 ligand-expressing cell line 
J558, after which the supernatant was analyzed for inflam-
matory cytokines. Immature IL-4 MoDC produced sig-
nificantly higher amounts of IL-6 (p = 0.04) and IL-12p70 
(p = 0.01) (Fig. 2a, immature) as compared to IFNα 
MoDC. No differences were observed in the secreted lev-
els of IL-1β, IL-8, IL-10, and TNFα, after CD40 ligation 
of immature MoDC (Fig. 2a, immature). CD40 ligation 
following MoDC maturation led to a small but significant 
increase in the production of IL-8 by IL-4 MoDC, com-
pared to IFNα MoDC. Mature IFNα MoDC produced mar-
ginally higher levels of IL-1β and considerably higher lev-
els of TNFα, compared to IL-4 MoDC (Fig. 2a, mature).
To determine the potency of IFNα or IL-4 MoDC, loaded 
with blebs, to prime T cells, we co-cultured fluorescently 
labeled allogeneic PBL with bleb-loaded mature MoDC at 
different ratios. After 6 days of co-culture, we analyzed the 
induced T cell proliferation (Fig. 2b, c), and analyzed the pro-
duced T cell cytokines. Mature IL-4 MoDC induced a signifi-
cant increase in CD3+ T cell proliferation over mature IFNα 
MoDC, whereas no significant differences could be detected 
between immature IFNα and IL-4 MoDC (Fig. 2b). The 
increase in T cell proliferation by mature IL-4 MoDC was 
attributable to the CD4+ T cell compartment, since no clear 
differences in proliferation could be detected within CD8+ T 
cell compartment (Fig. 2b). Analysis of the cytokines (IL-2, 
IL-4, IL-6, IL-10, IL-17a, TNFα, and IFNγ) produced by T 
cells after a 6-day co-culture with matured MoDC showed 
that despite a difference in proliferation, no significant 
differences were induced in the released T cell cytokines 
between the IFNα and IL-4 MoDC co-cultures (Fig. 2d).
IFNα MoDC have an increased capacity 
to cross‑present a MART‑1 synthetic long peptide, 
compared to IL‑4 MoDC
We next determined the capacity of MoDC to cross-present 
a 25-mer MART-1 SLP (aa16-40L) and MART-1 from 
blebs. To this end, immature HLA-A2+ MoDC were loaded 
overnight with either blebs (derived from a stably MART-
1-expressing AML HL60 cell line) or with the MART-1 
SLP, and maturation was induced 1 h post-loading. Loaded 
and matured MoDC were subsequently co-cultured for 5 h 
with a CD8+ cytotoxic T cell line, recognizing the MART-
1aa26-35 immunodominant epitope in an HLA-A2 restricted 
fashion (MART-1 CTL), after which the percentage of IFNγ 
producing MART-1 CTL was determined by intracellular 
staining using flow cytometry. Unfortunately, this method-
ology proved to lack the sensitivity to assess cross-presen-
tation efficiency of the MART-1aa26-35 epitope from blebs. 
While both IL-4 and IFNα MoDC were capable of cross-
presenting the MART-1aa26-35 epitope from the MART-1 
SLP, cross-presentation by IFNα MoDC was more efficient 
(Fig. 3a). The corresponding mean cross-presentation effi-
ciency, depicted as the IC50 value of the maximal IFNγ pro-
duction by the MART-1 CTL line (Fig. 3b), was 1.17 μg/
ml for IL-4 as compared to 0.63 μg/ml for IFNα MoDC 
(p = 0.07). These data demonstrate a clear trend toward a 
more efficient cross-presenting capacity of IFNα MoDC for 
soluble protein, in line with previous reports [13, 14].
IFNα and IL‑4 MoDC have similar capacities to prime 
antigen‑specific CD8+ T cells in vitro
We next assessed the ability of IFNα versus IL-4 MoDC to 
prime MART-1aa26-35-specific CD8
+ T cells. MoDC were 
loaded exogenously for 2 h with the 9-mer MART-1aa26-35L 
peptide, after which CD8+ T cells were primed and weekly 
restimulated with peptide-loaded IFNα and IL-4 MoDC, to 
analyze antigen-specific priming capacity in an autologous 
setting. From six healthy donors (six parallel wells per donor), 
we observed MART-1-specific CD8+ T cell expansion by spe-
cific HLA-A2 dextramer staining in 26/36 wells (72 %) and 
21/36 wells (58 %) for peptide-loaded IL-4 MoDC versus 
IFNα MoDC, respectively (Fig. 4a). In terms of percentage of 
CD8+ T cells staining dextramer positive, the average percent-
age per positive well (>0.1 % dextramer staining) was higher 
in the IFNα MoDC versus IL-4 MoDC co-cultures (mean 0.87 
vs. 0.43 % respectively, Fig. 4b). Due to high variability, nei-
ther of these differences reached statistical significance.
We managed to sort, expand, and test the avidity of IL-4 
versus IFNα MoDC-primed MART-1 dextramer-positive 
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CD8+ T cells in two out of six donors (Fig. 4c), revealing a 
higher functional avidity of the IL-4 MoDC-primed T cells 
in both instances (half max. IFNγ production at a mean of 
1.9 vs. 57.1 nM peptide for IL-4 and IFNα MoDC-primed 
T cells, respectively).
More efficient cross‑priming of antigen‑specific CD8+ T 
cells by bleb‑loaded IL‑4 MoDC
We next analyzed the capacity of both MoDC types to 
cross-prime MART-1 CD8+ T cells, after loading and 
maturing the MoDC overnight with MART-1-expressing 
HL60 AML blebs. Both MoDC types were capable of sub-
sequent priming of MART-1aa26-35-specific CD8
+ T cells. 
In contrast to peptide-loaded MoDC (Fig. 4a, b), the prim-
ing efficiency (mean 94 vs. 53 %, Fig. 5a, p = 0.06) and the 
mean percentage of MART-1-specific dextramer-positive 
CD8+ T cells (mean 0.56 vs. 0.12 %, Fig. 5b, p ≤ 0.05.) 
was higher when CD8+ T cells were primed with IL-4 
MoDC as compared to IFNα MoDC. However, CD8+ T 
cells primed with either MoDC type recognized their cog-
nate antigen with a similar avidity (Fig. 5c); of note, these 
Fig. 2  Cytokine production and T cell stimulation by MoDC. a 
Immature MoDC (left graph), or MoDC matured overnight using 
IL-1β, IL-6, TNFα, and PGE-2 (i.e., cytokine maturation cocktail, 
right graph), were ligated with CD40 in the presence of IFNγ, after 
which the produced cytokines were analyzed (n = 4). b MoDC were 
loaded with blebs in the absence (imMoDC) or presence (matMoDC) 
of the cytokine maturation cocktail, and subsequently co-cultured 
with fluorescently labeled allogeneic PBL in a mixed leukocyte reac-
tion (MLR). After 6 days, CD4+ and CD8+ T cell proliferation was 
analyzed using flow cytometry. c The gating strategy and representa-
tive example of CFSE dilution following a MLR. d The produced T 
cell cytokines were analyzed in the supernatant (n = 4). Statistical 
significance was for all figures determined using a Student’s t test
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T cell bulks were derived from the same donors as were the 
bulk cultures used for avidity analysis upon priming to the 
9-mer peptide (Fig. 4c).
Discussion
The need for targeting multiple TAA or preferably the uti-
lization of an individual’s unique mutanome for inducing 
tumor-directed immunity in vaccination strategies, has 
become evident in recent years [19, 20]. Tumor-derived 
“whole” cellular vaccines have therefore regained inter-
est, especially with the recent insights in immunogenic cell 
death [21]. We have previously reported on the beneficial 
effects of using apoptotic AML-derived blebs as a source of 
TAA for in situ loading of skin DC [11], as well as MoDC 
loading in vitro [6]. As MoDC cultured in the presence of 
GM-CSF and IFNα have been described to have a higher 
capacity for the cross-presentation of antigens [13, 14, 22, 
23], they might constitute a more potent platform for the 
delivery of blebs in the context of DC vaccination strate-
gies. We therefore conducted a head-to-head comparison of 
these MoDC subtypes.
The expression levels of cell surface antigens found 
were similar to those described in literature [12, 13], and 
importantly, loading of blebs did not interfere with matura-
tion of either MoDC type.
Our data clearly show that IL-4 MoDC are superior in 
taking up exogenous antigen, as the uptake of apoptotic 
blebs, pinocytosis, and receptor-mediated endocytosis were 
significantly increased, as compared to IFNα MoDC. This 
difference could not be related to differential expression of 
receptors previously reported to be involved in the uptake 
of apoptotic fragments, e.g., LOX-1, which we were una-
ble to detect. The observed lack of LOX-1 expression on 
IFNα (as well as IL-4) MoDC as compared to earlier stud-
ies might be explained by the IFN α-subunit and/or source 
used for differentiation. Whether this also explains the 
observation that IL-4 MoDC were more potent in ingestion 
apoptotic blebs remains unclear, since this difference might 
also be explained by the used antigen source: apoptotic 
blebs instead of apoptotic cells. Additionally, the modali-
ties used to induce MoDC maturation differ between the 
conducted studies and ours, which can result in functional 
differences. It will therefore be of interest to study the 
Fig. 3  Cross-presentation of a 25-mer synthetic long peptide (SLP) 
by MoDC. a Immature IL-4 (black bars) or IFNα MoDC (white 
bars) were loaded with a titration of MART-1: melanoma-associated 
antigen recognized by T cells 1 (MART-1) 25-mer SLP (aa16-40L). 
After loading and maturing overnight, MoDC were co-cultured with a 
MART-1 (aa26-35)-specific CD8+ T cell line, and intracellular IFNγ 
was quantified. Reactivity data at the highest MART-1 SLP concen-
tration (10 µg/ml) were set to 100 % and were, respectively, 53 and 
41 % of the total CD8+ MART-1 T cells after co-culture with IL-4 
or IFNα MoDC (n = 4). b The corresponding cross-presentation effi-
ciency plotted as the SLP concentration, at which 50 % of the CD8+ 
T cells produced IFNγ (IC50), where the percentage of IFNγ produc-
ing CD8+ T cells at 10 μg/ml was set to 100 % (n = 4). Statistical 
significance was determined using a Student’s t test
Fig. 4  MoDC priming efficiency and primed CD8+ T cell avidity. 
a The priming efficiency of six healthy donors was determined by 
analyzing the number of wells that were scored positive over time, 
as a percentage of the initiated number of wells, for both IL-4 (black 
bars) and IFNα MoDC (white bars; n = 36). b The percentages of 
MART-1 dextramer-positive CD8+ T cells per well, averaged over 
six donors. Statistical significance was determined using a Wilcoxon 
matched-pairs signed-rank test. c MART-1 dextramer-positive cells 
were sorted and expanded, after which their avidity was analyzed. 
Shown are the avidity assays of two donors in which we were able to 
prime, sort, and expand MART-1 dextramer-positive CD8+ T cells to 
sufficient numbers (n = 2)
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functional consequences of different activating stimuli on 
both types of MoDC in more detail. Moreover, since two 
types of DC are compared, some of the observed effects 
do not necessarily reflect a difference in IFNα MoDC, but 
could also reflect differences in the IL-4 MoDC. These 
differences in uptake did, however, not account for the 
observed higher priming efficiency of allogeneic CD4+ 
T cells per se, as unloaded IL-4 MoDC induced a simi-
larly elevated proliferation rate over IFNα MoDC (data 
not shown). The differences in T cell proliferation by IL-4 
MoDC could be a result of the more mature phenotype, in 
particular the increased expression levels of HLA class II, 
CD80, and CD83. Since we did not observe striking dif-
ferences in production of cytokines that we tested (IL-1β, 
IL-6, IL-8, IL-10, IL-12, and TNFα) by matured MoDC, 
this is not likely to result in altered T cell proliferation, 
although we did observe more robust production of TNFα 
by IFNα MoDC after maturation.
Despite the more efficient uptake of soluble antigens 
by IL-4 MoDC, IFNα MoDC displayed a higher ability 
to cross-present the MART-1aa26-35 epitope derived from 
a 25-mer MART-1 SLP, similar to what was described 
previously for OVA [14]. Although we observed a trend 
toward a higher mean outgrowth percentage of MART-
1-specific CD8+ T cells when priming with MART-1aa26-
35L peptide-loaded IFNα MoDC, the priming efficiency 
between IL-4 and IFNα MoDC was similar. However, the 
avidity of CD8+ T cells that were primed with peptide-
loaded IL-4 MoDC was higher compared to that of CD8+ 
T cells primed with IFNα MoDC (mean of ~2 vs. ~57 nM, 
respectively). The underlying mechanism leading to the 
higher avidity remains unclear, but it could be the result of 
the more mature phenotype of IL-4 MoDC, and possibly 
traces of the beneficial cytokines (IL-6 and especially IL-
12p70 [24]) as observed after CD40 ligation of immature 
IL-4 MoDC. Although the functional CD8+ T cell avid-
ity between bleb-loaded IL-4 and IFNα MoDC was very 
similar, a higher percentage of MART-1 positivity was 
achieved when primed with bleb-loaded IL-4 MoDC.
In this study, we used IFNα as a differentiation-inducing 
cytokine, but it will be of interest to analyze the effect of 
adding IFNα in the maturation cytokine cocktail of IL-4 
MoDC, on their cross-priming ability, since it has been 
shown that this has beneficial effects on CCR7 expression 
and T cell responses [25].
We show that both IFNα and IL-4 MoDC are efficient 
primers of CD8+ T cell responses. However, the choice 
of either MoDC type as vaccination vehicle depends on 
the antigen source used. SLP-based therapies could ben-
efit from using IFNα MoDC, whereas IL-4 MoDC appear 
better suited for cross-priming of CD8+ T cells to epitopes 
derived from apoptotic blebs, most likely due to their supe-
rior bleb uptake.
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Fig. 5  Cross-priming efficiency of bleb-loaded MoDC and resulting 
CD8+ T cell avidity. a The priming efficiency in six healthy donors 
was determined by analyzing the number of wells that were scored 
positive over time, as a percentage of the initiated number of wells, 
for both IL-4 (black bars) or IFNα MoDC (white bars; n = 36, i.e., 
six parallel wells per condition per donor). ***p ≤ 0.001 Fisher’s 
exact test. b The percentages of MART-1 dextramer-positive CD8+ 
T cells per well, averaged over six donors. *p ≤ 0.05 Wilcoxon 
matched-pairs signed-rank test C. MART-1 dextramer-positive cells 
were sorted and expanded, after which their avidity was analyzed. 
Shown are the avidity assays of two donors in which we were able to 
prime, sort, and expand MART-1 dextramer-positive CD8+ T cells to 
sufficient numbers (n = 2)
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